144 related articles for article (PubMed ID: 25514872)
1. TFF3 and HER2 expression and their correlation with survival in gastric cancer.
Gu J; Zheng L; Zhang L; Chen S; Zhu M; Li X; Wang Y
Tumour Biol; 2015 Apr; 36(4):3001-7. PubMed ID: 25514872
[TBL] [Abstract][Full Text] [Related]
2. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis.
Im S; Yoo C; Jung JH; Choi HJ; Yoo J; Kang CS
Int J Med Sci; 2013; 10(2):133-40. PubMed ID: 23329884
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
5. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis.
Dhar DK; Wang TC; Tabara H; Tonomoto Y; Maruyama R; Tachibana M; Kubota H; Nagasue N
Clin Cancer Res; 2005 Sep; 11(18):6472-8. PubMed ID: 16166422
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of HER2 and downstream proteins in prediction of advanced tumor phenotypes and overall survival of patients with Epstein-Barr virus-positive vs. negative gastric cancers.
Zhang YW; He D; Tan C; Dong M; Zhou L; Shao CK
Pathol Res Pract; 2019 Nov; 215(11):152675. PubMed ID: 31594682
[TBL] [Abstract][Full Text] [Related]
7. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
Wang Y; He L; Cheng Y
Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
[TBL] [Abstract][Full Text] [Related]
8. Impact of NPM, TFF3 and TACC1 on the prognosis of patients with primary gastric cancer.
Ding A; Zhao W; Shi X; Yao R; Zhou F; Yue L; Liu S; Qiu W
PLoS One; 2013; 8(12):e82136. PubMed ID: 24358147
[TBL] [Abstract][Full Text] [Related]
9. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
[TBL] [Abstract][Full Text] [Related]
10. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.
Subasinghe D; Sivaganesh S; Samarsekera A; Kumarasinghe MP; Samarasekera DN; Lokuhetty MDS
Dig Dis Sci; 2017 Sep; 62(9):2498-2510. PubMed ID: 28612195
[TBL] [Abstract][Full Text] [Related]
11. [HER2 expression in gastric cancer in Peru].
Beltran Gárate B; Yabar Berrocal A
Rev Gastroenterol Peru; 2010; 30(4):324-7. PubMed ID: 21263759
[TBL] [Abstract][Full Text] [Related]
12. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.
Qian J; Zhu W; Wang K; Ma L; Xu J; Xu T; Røe OD; Li A; Zhou J; Shu Y
Oncotarget; 2016 Jun; 7(24):36865-36884. PubMed ID: 27167206
[TBL] [Abstract][Full Text] [Related]
13. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
[TBL] [Abstract][Full Text] [Related]
14. The value of trefoil factor 3 expression in predicting the long‑term outcome and early recurrence of colorectal cancer.
Morito K; Nakamura J; Kitajima Y; Kai K; Tanaka T; Kubo H; Miyake S; Noshiro H
Int J Oncol; 2015 Feb; 46(2):563-8. PubMed ID: 25405728
[TBL] [Abstract][Full Text] [Related]
15. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
16. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues.
Leung WK; Yu J; Chan FK; To KF; Chan MW; Ebert MP; Ng EK; Chung SC; Malfertheiner P; Sung JJ
J Pathol; 2002 Aug; 197(5):582-8. PubMed ID: 12210076
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.
Dang HZ; Yu Y; Jiao SC
World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433
[TBL] [Abstract][Full Text] [Related]
18. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
19. Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis.
Wu H; Cai Z; Lu G; Cao S; Huang H; Jiang Y; Sun W
Tumori; 2017 May; 103(3):249-254. PubMed ID: 26549693
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
Grabsch H; Sivakumar S; Gray S; Gabbert HE; Müller W
Cell Oncol; 2010; 32(1-2):57-65. PubMed ID: 20208134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
